News & Stories

See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.

Chief Science Officer comments on recent work

Nov 11, 2019 | CMT Research Updates, Press Releases, Research News

CMT Research Foundation Chief Science Officer Grace Pavlath, PhD comments on recent work by Morelli et al: Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models Some types of CMT result from the expression of a mutant...

Emerging Landscape of Modifier Genes in CMT

Oct 21, 2019 | CMT Research Updates, Press Releases, Research News

In CMT, there is a large variation in disease onset, severity, or progression, often seen among individuals with the same genetic subtype of a disease, even within a single family. Genetic modifiers play important roles in such variations, known as heterogeneity....

Inherited Neuropathy Consortium Awarded $7.2M to Continue Studying, Improve Care for CMT

Oct 11, 2019 | CMT Research Updates, Press Releases, Research News

The National Institutes of Health has awarded the Inherited Neuropathies Consortium (INC) $7.2M over the next five years. This grant will be focused on improving clinical care and clinical research for CMT. The CMT Research Foundation is a proud partner of the INC....

Where is the Progress? The Cure For CMT Calls For Collaboration

Oct 11, 2019 | CMT Research Updates, Press Releases, Research News

More collaboration within the CMT research and patient community would help us get to treatments and a cure much faster. Thomas Durcan, an Assistant Professor for neurodegenerative disorders at McGill University recently wrote a very interesting appeal for...

AcuraStem Achieves First Milestone

Sep 18, 2019 | CMT Research Updates, Press Releases, Research News

Just nine months ago, we announced a milestone-based, research collaboration with AcuraStem to test thousands of compounds aimed at producing effective treatments for CMT2A. We are very pleased to report that AcuraStem has completed phase one of the CMT2A project. To...

Roadblocks on the Road to Curing Charcot-Marie-Tooth (CMT)

Sep 11, 2019 | CMT Research Updates, Press Releases, Research News

It seems like every other day we hear about a new drug that has been approved for a rare neurologic disease. Increased understanding of the genetics underlying these diseases has led to numerous new gene therapies. Why have we not yet seen similar successes in CMT? In...

CMT1A Research Update

Sep 2, 2019 | CMT Research Updates, Press Releases, Research News

CMT1A is caused by a duplication of the PMP22 gene leading to overexpression of the PMP22 protein and failure of the Schwann cells to produce myelin (the insulation of the nerve) well. Without proper myelination, the nerves don’t send signals quickly or strongly,...

CMT1B project is funded & ready for take off!

Aug 2, 2019 | CMT Research Updates, Press Releases, Research News

Paving pathways for mission critical projects CMT Research Foundation is partnering with Dr. Maurizio D’Antonio of I.R.C.C.S. Ospedale San Raffaele, in Milan, Italy to fund the lab’s research of Myelin Protein Zero (MPZ), the gene associated with CMT1B. Dr....

CMTRF Welcomes Dr. Grace Pavlath as Chief Science Officer

Jul 30, 2019 | CMT Research Updates, Press Releases

CMT Research Foundation (CMTRF), a not-for-profit organization focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, has added Grace Pavlath, Ph.D. to the team as the new Chief Scientific Officer. CMT is a progressive genetic nerve disease...

New research efforts by Neurogene, give hope to patients suffering with an ultra-rare type of CMT: CMT4J

Jul 19, 2019 | CMT Research Updates, Press Releases, Research News

Neurogene, a leading company developing genetic medicines for people with rare, devastating neurological diseases, announced today that it is recruiting patients for a natural history study for CMT4J. "Key data now being collected to support endpoint assessment for...